jama ophthalmology semaglutide Eye Risks of Ozempic: What You Need to Know About and NAION Eye Risks of Ozempic: What You Need to Know About Semaglutide and NAION Semaglutide use linked with increased

Since obesity is a chronic illness that can lead to type 2 diabetes, cardiovascular disease, certain cancers, and sleep disorders, the FDA responded by approving the use of semaglutide in increased dosages for treating obesity and overweight individuals with certain weight-related diseases

Interestingly, defects in mitochondrial energy metabolism are also present in the brains of patients with AD, leading to neuronal apoptosis and A deposition, which increases ROS production by interfering with mitochondrial calcium homeostasis and ETC function

We tapped registered dietitian Imashi Fernando, MS, RDN, CDCES to find out

The response has been remarkable